BPG is committed to discovery and dissemination of knowledge
Basic Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Cardiol. Nov 26, 2026; 18(11): 124181
Published online Nov 26, 2026. doi: 10.4330/wjc.124181
Xin-II shows cardioprotective effects in a rat model of chronic heart failure: An integrated network pharmacology and transcriptomic
Xi-Ju Liu, Yan Cong, Ran Zheng, Ming Li, Zhi Xiu, Peng-Fei Hu, Guo-Hua Wu, Cha-Gan Lianhua, Quan Wan
Xi-Ju Liu, Yan Cong, Ran Zheng, Ming Li, Zhi Xiu, School of Clinical Medicine, Inner Mongolia Minzu University, Tongliao 028000, Inner Mongolia Autonomous Region, China
Peng-Fei Hu, Guo-Hua Wu, Cha-Gan Lianhua, Quan Wan, Department of Cardiovascular Medicine, Affiliated Hospital of Inner Mongolia Minzu University, TongLiao 028000, Inner Mongolia Autonomous Region, China
Co-corresponding authors: Cha-Gan Lianhua and Quan Wan.
Author contributions: Liu XJ was instrumental and responsible for data re-analysis and re-interpretation, figure plotting, comprehensive literature search, preparation and submission of the current version of the manuscript; Liu XJ and Lianhua CG contributed to formal analysis; Liu XJ and Wan Q contributed to conducting the research, and writing original draft; Cong Y contributed to validation, visualization; Zheng R, Li M, Xiu Z and Hu PF contributed to data curation; Li M, Xiu Z and Wu GH contributed to investigation; Lianhua CG and Wan Q contributed to conceptualization and methodology as co-corresponding authors; Wan Q contributed to designing the research, project administration, writing-review and editing; all of the authors read and approved the final version of the manuscript to be published.
AI contribution statement: No AI tools were used to create the content of this manuscript.
Supported by The Youth Research Start-up Fund of the Affiliated Hospital of Inner Mongolia University for Nationalities, No. 2020QNJJ02.
Institutional animal care and use committee statement: The requirement for ethics approval was approved by the Animal Ethics Committee of Affiliated Hospital of Inner Mongolia Minzu University (approval No. NM-LL-2026-05-15-01).
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The raw RNA-seq data generated in this study have been deposited in the NCBI Gene Expression Omnibus under accession number GSE347459 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE347459) and will be publicly available upon publication. All other data supporting the findings of this study are available within the article and its Supplementary material.
Corresponding author: Quan Wan, PhD, Associate Chief Physician, Department of Cardiovascular Medicine, Affiliated Hospital of Inner Mongolia Minzu University, No. 1742 East Section of Huolinghe Street, TongLiao 028000, Inner Mongolia Autonomous Region, China. wanquan120@126.com
Received: June 9, 2026
Revised: August 13, 2026
Accepted: November 2, 2026
Published online: November 26, 2026
Processing time: 163 Days and 1.2 Hours
Core Tip

Core Tip: This study integrates network pharmacology and RNA-seq to reveal that Mongolian Medicine Xin-II alleviates chronic heart failure by modulating the peroxisome proliferator-activated receptor/hypoxia-inducible factor-1 signaling pathway, improving cardiac function and myocardial pathology.

Write to the Help Desk